Literature DB >> 9629401

Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. A double-blind trial.

C A Bordini1, M A Arruda, M C Ciciarelli, J G Speciali.   

Abstract

Fourty-five migraine without aura patients underwent a parallel double-blind trial aiming the comparison of the effects of propranolol 60 mg/day to flunarizine 10 mg/day and to propranolol 60 mg/day plus flunarizine 10 mg/day simultaneously. There were 3 groups, each one with 15 patients. After a 20-day-baseline period, each group received one kind of treatment during 120 days. Migraine index on propranolol was 23.4*, on flunarizine 18.7* and on both drugs 14.4*, mean frequency of attacks on propranolol was 1.26**, on flunarizine 1.2** and on both drugs 1.13** (*p < 0.05, **p < 0.01 compared to baseline) and global evaluation was reduced with all forms of treatment. It was not found statistical differences between groups, nevertheless there was a trend in the group using two drugs reaching lower values in migraine index, frequency of attacks and global evaluation. In individuals using flunarizine (alone or associated with propranolol) the therapeutic effect was largely maintained up to 45 days after drug withdrawal.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9629401     DOI: 10.1590/s0004-282x1997000400003

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  9 in total

Review 1.  Controversies in migraine: monotherapy.

Authors:  Domenico D'Amico
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

Review 2.  The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers.

Authors:  V Limmroth; M C Michel
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

Review 3.  When should "chronic migraine" patients be considered "refractory" to pharmacological prophylaxis?

Authors:  Domenico D'Amico; Massimo Leone; Licia Grazzi; Gennaro Bussone
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

4.  Protection of flunarizine on cerebral mitochondria injury induced by cortical spreading depression under hypoxic conditions.

Authors:  Fengpeng Li; Enchao Qiu; Zhao Dong; Ruozhuo Liu; Shiwen Wu; Shengyuan Yu
Journal:  J Headache Pain       Date:  2011-02-25       Impact factor: 7.277

5.  A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache.

Authors:  Jeffrey L Jackson; Elizabeth Cogbill; Rafael Santana-Davila; Christina Eldredge; William Collier; Andrew Gradall; Neha Sehgal; Jessica Kuester
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

6.  Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis.

Authors:  Jeffrey L Jackson; Akira Kuriyama; Yachiyo Kuwatsuka; Sarah Nickoloff; Derek Storch; Wilkins Jackson; Zhi-Jiang Zhang; Yasuaki Hayashino
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

7.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

8.  Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine.

Authors:  Abouch Valenty Krymchantowski; Marcelo Eduardo Bigal
Journal:  BMC Neurol       Date:  2004-06-28       Impact factor: 2.474

9.  Development and Validation of a HPTLC Method for Simultaneous Quantitation of Flunarizine Dihydrochloride and Propranolol Hydrochloride in Capsule Dosage Form.

Authors:  N A Shivarkar; P B Dudhe; M A Nagras
Journal:  Indian J Pharm Sci       Date:  2013-05       Impact factor: 0.975

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.